4D Molecular Therapeutics, Inc. (FDMT)

In October 2025, the company secured an equity investment from the Cystic Fibrosis Foundation. In November 2025, executive changes and concerns over trial data led to a stock decline. In January 2026, Barclays initiated coverage with an "overweight" rating. In March 2026, the company reported full-year 2025 financial results, while Jefferies cut its price target and RBC Capital raised its target. In April 2026, a Janus Henderson filing disclosed a stake in the company, leading to a stock gain, and the company disclosed RSUs granted to new hires. In May 2026, 4D Molecular Therapeutics reported its Q1 2026 results, with a net loss, and Wall Street Zen downgraded the stock.

As a clinical-stage gene therapy company without commercial products, 4D Molecular Therapeutics does not have demand seasonality in a traditional sense. Its revenue comes from collaborations and licensing, and its operations are funded through capital raising and cash reserves. Its success depends on clinical trial outcomes and regulatory approvals.

4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company focused on developing customized AAV vectors and product candidates, operating in the Healthcare sector and Biotechnology industry. The company uses its Therapeutic Vector Evolution platform to create gene therapies for rare and large market diseases by targeting specific tissues. Its pipeline includes 4D-150 in Phase 3 trials for wet AMD and DME, 4D-710 in clinical development for cystic fibrosis, 4D-310 in Phase 1/2 for Fabry disease cardiomyopathy, 4D-125 in Phase 1/2 for XLRP, 4D-110 in Phase 1 for choroideremia, 4D-175 in preclinical development for GA, and 4D-725 in preclinical development for alpha-1 antitrypsin deficiency lung disease.

4D Molecular Therapeutics' core operations are located in Emeryville, California, providing access to talent and research institutions. While its physical footprint is U.S.-based, its impact is global through international clinical trials and collaborations, such as with Otsuka Pharmaceutical Co., Ltd. for the Asia-Pacific region.

4D Molecular Therapeutics has been assessed as "Lower Risk" regarding corporate weaponization and discriminatory philanthropy, but received a "High Risk" rating for employment protection. The company emphasizes its patient-focused approach and commitment to innovation.

The ownership of 4D Molecular Therapeutics is a mix of institutional, insider, and retail investors. Institutional investors own approximately 32.09% to 80.75% of the stock, insiders own 2.45% to 19.25%, and public companies and individual investors own 18.02% to 65.46%. Major institutional shareholders include Ra Capital Management, L.P., Janus Henderson Group Plc, and BVF Inc/il. Peter Kolchinsky owns the most shares, and CEO David Kirn holds 3.0% of the shares.